Marquette Asset Management LLC Makes New $122,000 Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Marquette Asset Management LLC acquired a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,866 shares of the company’s stock, valued at approximately $122,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. nVerses Capital LLC raised its position in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd purchased a new position in iTeos Therapeutics in the 3rd quarter worth about $31,000. China Universal Asset Management Co. Ltd. raised its holdings in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after buying an additional 2,646 shares during the period. Virtu Financial LLC acquired a new stake in iTeos Therapeutics during the 3rd quarter worth about $102,000. Finally, Quest Partners LLC lifted its stake in iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock valued at $113,000 after buying an additional 9,934 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insider Buying and Selling

In other news, CFO Matthew Gall bought 5,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $7.73 per share, with a total value of $38,650.00. Following the transaction, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 12.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a report on Friday, December 13th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $7.66 on Wednesday. The firm has a market capitalization of $279.85 million, a price-to-earnings ratio of -2.43 and a beta of 1.39. The company has a 50 day simple moving average of $8.08 and a 200-day simple moving average of $11.64. iTeos Therapeutics, Inc. has a 52-week low of $7.09 and a 52-week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. On average, analysts predict that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.